San Francisco-based Trace Neuroscience has launched with $101 million in series A funding to develop ALS therapies focused on ...

Novel MEK blocker shows promise in rare genetic disorder ...

While not everything appears rosy in one of AstraZeneca’s (LSE: AZN) major markets, the company has announced a huge ...

German life sciences company Merck KGaA (MRK: DE) today announced that the Phase III MANEUVER trial of pimicotinib met its ...

RAPT Therapeutics has ended its zelnecirnon program following safety concerns raised by the FDA after a severe adverse event ...

Germany’s Bayer saw its shares tumble almost 11% to 21.76 euros this morning, as it reported level third-quarter 2024 sales ...

Anglo-Swedish drugmaker AstraZeneca (LSE: AZN) beat analyst expectations with its third-quarter revenue and earnings figures.

French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today ...

Me is restructuring, cutting 40% of its workforce, ending its therapeutics programs, and refocusing on its consumer genetics ...

Twelve leading health economists have published a paper in the Forum for Health Economics and Policy that challenges the drug ...

The Chicago-based firm earlier announced that its two Phase II EMPOWER trials investigating emraclidine as a once-daily, oral ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...